Development and Characterisation of a Box-Behnken Optimised Polymeric Matrix Transdermal Patch of Aripiprazole: Ex Vivo Permeation, Stability and Skin Tolerability

References

[1] Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381–9. https://doi.org/10.1124/jpet.102.033175

[2] Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763–71.

[3] Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715–36. https://doi.org/10.2165/00003495-200464150-00010

[4] Kim JR, Seo HB, Cho JY, Kang DH, Kim YK, Bahk WM, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol. 2008;66(6):802–10. https://doi.org/10.1111/j.1365-2125.2008.03223.x

[5] Hendset M, Hermann M, Lunde H, Refsum H, Molden E. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol. 2007;63(12):1147–51. https://doi.org/10.1007/s00228-007-0373-6

[6] Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62. https://doi.org/10.2147/PROM.S42735

[7] Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. https://doi.org/10.1016/S2215-0366(21)00039-0

[8] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8. https://doi.org/10.1038/nbt.1504

[9] Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–9. https://doi.org/10.1034/j.1600-0625.2000.009003165.x

[10] Abruzzo A, Cerchiara T, Luppi B, Bigucci F. Transdermal delivery of antipsychotics: rationale and current status. CNS Drugs. 2019;33(9):849–65. https://doi.org/10.1007/s40263-019-00659-7

[11] Citrome L, Walling DP, Zeni CM, Starling BR, Terahara T, Kuriki M, et al. Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: a phase 3, randomized, placebo-controlled study. J Clin Psychiatry. 2021;82(1):20m13602. https://doi.org/10.4088/JCP.20m13602

[12] Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, et al. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res. 2020;215:408–15. https://doi.org/10.1016/j.schres.2019.07.055

[13] Hossain MA, Ahmed SU, Plakogiannis FM. Effect of vehicle systems, pH and enhancers on the permeation of highly lipophilic aripiprazole from Carbopol 971P gel systems across human cadaver skin. Drug Dev Ind Pharm. 2012;38(3):323–30. https://doi.org/10.3109/03639045.2011.602978

[14] Latif MS, Azad AK, Nawaz A, Rashid SA, Rahman MH, Al Omar SY, et al. Ethyl cellulose and hydroxypropyl methyl cellulose blended methotrexate-loaded transdermal patches: in vitro and ex vivo. Polymers (Basel). 2021;13(20):3455. https://doi.org/10.3390/polym13203455

[15] Nandi S, Mondal S. Fabrication and evaluation of matrix type novel transdermal patch loaded with tramadol hydrochloride. Turk J Pharm Sci. 2022;19(5):572–82. https://doi.org/10.4274/tjps.galenos.2021.43678

[16] Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603–18. https://doi.org/10.1016/j.addr.2003.10.025

[17] Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics. 1960;2(4):455–75. https://doi.org/10.1080/00401706.1960.10489912

[18] Ferreira SLC, Bruns RE, Ferreira HS, Matos GD, David JM, Brandão GC, et al. Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta. 2007;597(2):179–86. https://doi.org/10.1016/j.aca.2007.07.011

[19] Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781–91. https://doi.org/10.1007/s11095-007-9511-1

[20] International Council for Harmonisation. ICH Q2(R1): Validation of analytical procedures: text and methodology. Geneva: ICH; 2005.

[21] Franz TJ. Percutaneous absorption. On the relevance of in vitro data. J Invest Dermatol. 1975;64(3):190–5. https://doi.org/10.1111/1523-1747.ep12533356

[22] Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52(12):1145–9. https://doi.org/10.1002/jps.2600521210

[23] Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35. https://doi.org/10.1016/0378-5173(83)90064-9

[24] Guth K, Schäfer-Korting M, Fabian E, Landsiedel R, van Ravenzwaay B. Suitability of skin integrity tests for dermal absorption studies in vitro. Toxicol In Vitro. 2015;29(1):113–23. https://doi.org/10.1016/j.tiv.2014.09.007

[25] International Council for Harmonisation. ICH Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH; 2003.

[26] International Council for Harmonisation. ICH Q1B: Stability testing: photostability testing of new drug substances and products. Geneva: ICH; 1996.

[27] OECD. Test No. 439: In vitro skin irritation: reconstructed human epidermis test method. OECD Guidelines for the Testing of Chemicals, Section 4. Paris: OECD Publishing; 2025. https://doi.org/10.1787/9789264242845-en

[28] Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–90.

[29] OECD. Test No. 404: Acute dermal irritation/corrosion. OECD Guidelines for the Testing of Chemicals, Section 4. Paris: OECD Publishing; 2015. https://doi.org/10.1787/9789264242678-en

[30] Arora P, Mukherjee B. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci. 2002;91(9):2076–89. https://doi.org/10.1002/jps.10200

[31] Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm. 2006;64(1):1–8. https://doi.org/10.1016/j.ejpb.2006.03.009

[32] Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011;418(1):6–12. https://doi.org/10.1016/j.ijpharm.2011.03.051

[33] Gannu R, Vishnu YV, Kishan V, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Curr Drug Deliv. 2007;4(1):69–76. https://doi.org/10.2174/156720107779314767

[34] Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res. 1991;8(3):350–4. https://doi.org/10.1023/A:1015845632280

[35] Naik A, Pechtold LARM, Potts RO, Guy RH. Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. J Control Release. 1995;37(3):299–306. https://doi.org/10.1016/0168-3659(95)00088-7

[36] Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152–61. https://doi.org/10.1016/j.addr.2007.07.004

[37] Spielmann H, Hoffmann S, Liebsch M, Botham P, Fentem JH, Eskes C, et al. The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. Altern Lab Anim. 2007;35(6):559–601.

[38] Khire A, Vavia P. Bioavailability, bioequivalence, and in vitro-in vivo correlation of oxybutynin transdermal patch in rabbits. Drug Deliv Transl Res. 2014;4:105–15. https://doi.org/10.1007/s13346-013-0170-y

[39] Alkilani AZ, McCrudden MTC, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7(4):438–70. https://doi.org/10.3390/pharmaceutics7040438

@article{1724046,
      author = {Arav Mishra, Vishal Kumar Singh},
      title = {Development and Characterisation of a Box-Behnken Optimised Polymeric Matrix Transdermal Patch of Aripiprazole: Ex Vivo Permeation, Stability and Skin Tolerability},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {4},
      pages = {2466-2475},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1724046.pdf},
      abstract = {Oral aripiprazole is limited by hepatic first-pass metabolism, CYP2D6-dependent exposure and the poor adherence that characterises long-term antipsychotic therapy. This study developed and characterised a polymeric matrix transdermal patch of aripiprazole by solvent casting. Preformulation work confirmed a lipophilic drug (log P 4.18 ± 0.09) that was compatible with all excipients, and a stability-indicating RP-HPLC method was validated (R² = 0.9999; recovery 99.6–100.2%; RSD ≤ 0.89%). Eight screening batches identified an HPMC K4M : ethyl cellulose N10 matrix as the most suitable base, and a 17-run, three-factor Box-Behnken design (polymer ratio, PEG 400 and oleic acid) was used for optimisation. The optimised patch (HPMC:EC 60:40, PEG 400 22% w/w, oleic acid 6% w/v) matched model predictions within 2.2% and showed drug content of 99.2 ± 0.4%, tensile strength of 4.08 ± 0.18 N/mm², folding endurance of 354 ± 18 and a surface pH of 6.28 ± 0.08. It released 73.4 ± 1.6% of the drug in 24 h by anomalous (non-Fickian) transport (Korsmeyer-Peppas n = 0.58) and, through excised rat skin, gave a steady-state flux of 17.8 ± 0.9 µg/cm²/h with an enhancement ratio of 1.93. Drug content remained at or above 95% after 6 months at 40 °C/75% RH and after 12 months at 25 °C/60% RH, although photostability testing showed that light protection is required. The patch was non-irritant in a reconstructed human epidermis model (viability 82.4 ± 4.1%) and in rabbits (primary irritation index 0.24). The findings support progression to in vivo pharmacokinetic evaluation.},
      keywords = {aripiprazole; transdermal patch; HPMC; ethyl cellulose; oleic acid; Box-Behnken design; skin permeation; stability; skin irritation},
      month = {October},
  }